全文获取类型
收费全文 | 2654篇 |
免费 | 281篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 184篇 |
妇产科学 | 36篇 |
基础医学 | 345篇 |
口腔科学 | 204篇 |
临床医学 | 319篇 |
内科学 | 569篇 |
皮肤病学 | 52篇 |
神经病学 | 179篇 |
特种医学 | 182篇 |
外科学 | 345篇 |
综合类 | 103篇 |
一般理论 | 1篇 |
预防医学 | 174篇 |
眼科学 | 48篇 |
药学 | 103篇 |
中国医学 | 2篇 |
肿瘤学 | 109篇 |
出版年
2023年 | 17篇 |
2022年 | 20篇 |
2021年 | 34篇 |
2020年 | 24篇 |
2019年 | 24篇 |
2018年 | 67篇 |
2017年 | 64篇 |
2016年 | 68篇 |
2015年 | 76篇 |
2014年 | 119篇 |
2013年 | 150篇 |
2012年 | 110篇 |
2011年 | 88篇 |
2010年 | 112篇 |
2009年 | 119篇 |
2008年 | 85篇 |
2007年 | 111篇 |
2006年 | 107篇 |
2005年 | 72篇 |
2004年 | 86篇 |
2003年 | 62篇 |
2002年 | 74篇 |
2001年 | 53篇 |
2000年 | 49篇 |
1999年 | 54篇 |
1998年 | 113篇 |
1997年 | 103篇 |
1996年 | 109篇 |
1995年 | 72篇 |
1994年 | 83篇 |
1993年 | 46篇 |
1992年 | 39篇 |
1991年 | 38篇 |
1990年 | 36篇 |
1989年 | 44篇 |
1988年 | 52篇 |
1987年 | 53篇 |
1986年 | 42篇 |
1985年 | 30篇 |
1984年 | 25篇 |
1983年 | 13篇 |
1982年 | 26篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1978年 | 16篇 |
1977年 | 15篇 |
1976年 | 21篇 |
1975年 | 12篇 |
1974年 | 10篇 |
1966年 | 12篇 |
排序方式: 共有2972条查询结果,搜索用时 15 毫秒
101.
102.
Maryline Fresquet Thomas A. Jowitt Jennet Gummadova Richard Collins Ronan O’Cualain Edward A. McKenzie Rachel Lennon Paul E. Brenchley 《Journal of the American Society of Nephrology : JASN》2015,26(2):302-313
Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of patients with idiopathic membranous nephropathy. We describe the location of a major epitope in the N-terminal cysteine-rich ricin domain of PLA2R that is recognized by 90% of human anti-PLA2R autoantibodies. The epitope was sensitive to reduction and SDS denaturation in the isolated ricin domain and the larger fragment containing the ricin, fibronectin type II, first and second C-type lectin domains (CTLD). However, in nondenaturing conditions the epitope was protected against reduction in larger fragments, including the full-length extracellular region of PLA2R. To determine the composition of the epitope, we isolated immunoreactive tryptic fragments by Western blotting and analyzed them by mass spectrometry. The identified peptides were tested as inhibitors of autoantibody binding to PLA2R by surface plasmon resonance. Two peptides from the ricin domain showed strong inhibition, with a longer sequence covering both peptides (31-mer) producing 85% inhibition of autoantibody binding to PLA2R. Anti-PLA2R antibody directly bound this 31-mer peptide under nondenaturing conditions and binding was sensitive to reduction. Analysis of PLA2R and the PLA2R-anti-PLA2R complex using electron microscopy and homology-based representations allowed us to generate a structural model of this major epitope and its antibody binding site, which is independent of pH-induced conformational change in PLA2R. Identification of this major PLA2R epitope will enable further therapeutic advances for patients with idiopathic membranous nephropathy, including antibody inhibition therapy and immunoadsorption of circulating autoantibodies. 相似文献
103.
104.
105.
106.
107.
In two previous studies, we observed that recombinant human interleukin- 3 (IL-3) induced an increase in marrow burst-forming unit-erythroid- derived colonies in vitro in some patients with Diamond-Blackfan anemia (DBA). To determine whether a similar erythropoietic response could be induced in vivo, we treated 13 patients with DBA (aged 4 to 19 years) with two preparations of IL-3. All patients had absent absolute reticulocyte counts and markedly reduced to absent recognizable bone marrow erythroid elements; patients with circulating reticulocytes in the previous 12 months were excluded from study. All patients except 1 had failed steroid therapy and had been transfusion-dependent since infancy; 1 patient was maintained on high-dose prednisone at the time of enrollment. On the first arm of the study, IL-3 (Immunex Corp, Seattle, WA) was administered subcutaneously using a dose escalation regimen of 125 to 500 micrograms/m2/day in divided dosage at 12-hour intervals, coadministered with 1.5 mg/kg/d of oral ferrous sulphate. Of the 13 patients that entered the trial, 4 stopped prematurely because of adverse side effects. In the other 9 evaluable cases, reticulocytes increased transiently in 1 patient from 0 to 65 x 10(9)/L after 35 days of IL-3 therapy at 250 micrograms/m2, but transfusion dependency persisted. One transient peak in absolute reticulocyte count was noted in 6 other patients, but no erythroid response was observed after completion of a full course of IL-3. Oral prednisone at 0.5 mg/kg/d was then coadministered with IL-3 at 500 micrograms/m2 to 5 of the patients without effect, and treatment was stopped. In 2 patients, a second preparation of IL-3 (Sandoz Canada Inc, Dorval, Quebec, Canada) was initiated in a dose escalation regimen of 2.5 to 10 micrograms/kg and was coadministered with ferrous sulphate. No erythroid response was observed in either patient, and in one of the two, alternate-day subcutaneous recombinant erythropoietin at 300 U/kg was administered for 3 weeks in combination with daily IL-3 at 10 micrograms/kg, but no increased erythropoiesis was seen. Significant increases in white blood cell and eosinophil counts during administration of both preparations of IL-3 were observed in all patients. These data show that the response of DBA patients to IL-3 in vivo is heterogeneous and cannot be predicted from in vitro studies. The absence of a corrective effect of IL-3 in these patients with DBA indicates that a deficiency of the cytokine is not central in the pathogenesis of the disorder. 相似文献
108.
109.
110.
Flora Maria Lorenzo Fortes Ney Boa Sorte Victor D Mariano La la D Andrade Fernanda A Oliveira Monique CA Santos Cl udia Ivanilda N dos Santos Catharina A Passos Mila P Pacheco Valdiana C Surlo Neog lia P de Almeida Jaciane AM Fontes r a M Pimentel Raquel Rocha Genoile Oliveira Santana 《World journal of gastroenterology : WJG》2020,26(44):6993-7004
BACKGROUNDThere has been an increase in cases of inflammatory bowel disease (IBD) in recent years. There is also greater access and availability of immunosuppressive and biological agents, which increase the risk of opportunistic infection despite improving the quality of life and promoting mucosal healing. Tuberculosis (TB) remains a public health problem, and it has a high incidence in several countries. Therefore, knowledge of the risk of developing TB in patients with IBD is important.AIMTo evaluate the risk of active TB in patients with IBD under treatment from an endemic area in Latin America.METHODSA standard questionnaire included demographic variables, clinical aspects of IBD disease, history of active TB during treatment, active TB characteristics and evolution, initial screening and results and time from the start of anti-tumor necrosis factor alpha (TNFα) to TB development.RESULTSAzathioprine, anti-TNFα and the combination of these two drugs were associated with a higher risk of active TB incidence. The TNFα blockers increased the relative risk of developing active TB compared to other treatments. All four multivariable models showed that the use of TNFα blockers alone or in combination with azathioprine was an important risk factor for the incidence of active TB. After adjustment for sex, age, type of IBD and latent TB, anti-TNFα with azathioprine increased the relative risk to 17.8 times more than conventional treatment. Late TB, which was diagnosed 3 mo after the start of anti-TNFα, was the most frequent.CONCLUSIONTreatment with anti-TNFα increased the risk of active TB in IBD patients from an endemic area in Latin America. This risk was increased when anti-TNFα was combined with azathioprine. The time from the beginning of the treatment to the active TB diagnosis suggests a new TB infection. 相似文献